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Poster Session-II 131CB and ex vivo CB as well as peripheral blood mononuclear cells
(PBMC) as controls. T cell receptor spectratyping was performed
before and after expansion with aim to determine usage of different
TCR Vbetas.
Results:T cells expanded with a median of 148-fold over a period
of 8–11 days. Expanded preparations contained 99% of CD31 cells
without signs for significant expansion of CD191 or CD3-/CD561
cells. CD4/CD8 ratio of expanded T cells was not altered signifi-
cantly when compared to CB ex vivo (a mean of 1,7 to 2,02, respec-
tively). The majority of T cells were positive for ab T cell receptor
(93%). Up to 85% of expanded T cells were CD251, 3% of
CD31 fraction were CD251/FoxP31. Expanded T cells, when
stimulated with CD3-beads, produced IL-2, IFN-g, TNF-a in
a cell to bead ratio in a dose-dependant manner at higher levels, com-
paraed to peripheral T cells and CB ex vivo T cells. TCR spectratyp-
ing has shown a polyclonal pattern of TCR Vbeta-gene usage in the
expanded T cell pool.
Conclusions: We have successfully set up a clinically feasible sys-
tem of T cell expansion for use as DLI after CBT. The expansion
procedure has not introduced major phenotypic changes when com-
pared to CB cells ex vivo. Expanded cells are functional in terms of
cytokine production and display no oligoclonal pattern of TCR us-
age. Expanded CB T lymphocytes may serve as a possibility for DLI
after CBT.365
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The pathophysiology of chronic (c) Graft-versus-Host Disease
(GVHD) is poorly understood. The protean nature of the syn-
drome suggests more complex mechanisms than pure T cell (TC)
effects. We analyzed cellular infiltrates of hematolymphoid tissues
(bone marrow (BM), spleen, lymph nodes (LN), thymus, liver) after
hematopoietic cell transplantation (HCT) in 3 minor-mismatched
mouse models of GVHD. Myeloablated BALB.B (H2b), BALB/c
(H2d), and BALB.K (H2k) mice were given purified hematopoietic
stem cells 1 splenocytes (SP) from C57BL/6 (B6), B10.D2, or
AKR/J donors, respectively. BALB.B recipients developed acute
and chronic GVHD. BALB/c mice showed skin lesions on ears
and tail, which resolved by d50, but no systemic or late symptoms.
Despite a lower SP dose BALB.K hosts developed fulminant
GVHD. Differences in type and kinetics of cellular infiltration of
organs were observed between the strains. In all 3 models BM
was a major site of donor (do) TC infiltration early post-HCT.
While B cell (BC) reconsititution was severely delayed BALB.B
BM contained 50% doTC, which were in 60% CD81 (effector
memory (EM) phenotype), and H60 tetramer-reactive in up to
24%. At a low level doTC persisted long-term in the BM.
BALB/c recipients of B10.D2 grafts had better BC regeneration
and less infiltrating doTC (40%). The latter were CD4/8 balanced
and normalized promptly (d50 \3%). In contrast, BALB.K mice
given AKR/J grafts, had prominent CD4 (EM) doTC infiltrates.
The liver was a main target of GVH in BALB.B recipients: 14d
post-HCT liver MNC contained 60–80% doTC, 30% reactive to
H60. Low levels of infiltration were observed long-term. In
BALB/c livers Mac1/Gr11 cells predominated (\60%), while
doTC infiltration was less severe and resolved completely. BALB.K
livers contained 80% doTC, mostly CD41. Thymuses, spleen
and LN of BALB.B and K recipients were hypoplastic, hypocellular
and infiltrated by doTC with a decreased CD4/811 fraction.
BALB.K LN had predominantly CD4 doTC and lacked BC, while
BALB.B LN contained CD8.CD4. Thymuses, spleen and LN of
BALB/c recipients normalized after some initial doTC infiltration.
In conclusion, hematolymphoid organs can be GVH targets, which
is associated with impaired hematopoietic and immune reconstitu-
tion. Damage of these tissues may disturb normal immunity, and
via dysfunctional immune education indirectly contribute to auto-
immune-like phenomena as seen in chronic GVHD.366
FEASABILITY OF EXTRACORPOREAL PHOTOPHERESIS IN MANAGING PA-
TIENTS WITH BRONCHIOLITIS OBLITERANS FOLLOWING ALLOGENEIC
STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
Rome, A.M., Toor, A.A., Chung, H., Roseff, S.D., Edwards, R.,
Lamberta, J., Anderson, J., Candler, K., McCarty, J.M. Virginia Com-
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Introduction: Bronchiolitis obliterans (BO) is a serious, often fa-
tal complication of allogeneic stem cell transplantation (SCT). Most
patients do not respond to conventional immunosuppressive ther-
apy. We retrospectively reviewed records of patients with BO treated
with extracorporeal photopheresis (ECP), given its efficacy in man-
aging chronic corticosteroid refractory cutaneous, oral, and hepatic
graft versus host disease (GVHD).
Patients and Methods: Forty two patients were treated at our
center for chronic GVHD with ECP from 2003–2007. Thirteen pa-
tients (31%) met diagnostic criteria for BO defined as the presence of
pulmonary symptoms, hypoxemia and one of the following 1) de-
crease in FEV1 by.20% or 2) air-trapping, small airway thickening
or bronchiectasis on lung CT without evidence of an infection. ECP
was performed on 2 consecutive days every 2 weeks for the first 4
months and less frequently thereafter.
Results: Nine of thirteen patients met criteria due to decrease in
FEV1 and lung changes on CT; 4 due to radiographic findings alone.
ECP was initiated at a median of 954 days (range, 173–2122 days) af-
ter allogeneic SCT (11 matched related donors, 2 unrelated donors).
All but one patient had failed prior corticosteroid-based immuno-
suppressive therapy. With a median follow-up of 782 days from di-
agnosis of BO, 11/13 (85%) of the patients are alive. Seven of
thirteen (54%) patients had a 50% decrease in steroid dosage without
deterioration of pulmonary function; 3/13 (23%) patients had im-
provement of radiographic abnormalities; 4/7 (57%) patients with
oxygen requirements prior to initiation of ECP were completely ti-
trated off oxygen. No patients had a decline in pulmonary function
tests despite steroid withdrawal. Only 3 patients experienced grade
III or higher adverse events related to the indwelling catheter (3 in-
fectious, 1 bleeding and 2 thromboses). Two of thirteen patients
died, one due to progression of BO and 1 from pneumonia. Our ob-
served survival rate of 85% in patients with BO is in contrast to the
44–73% survival rate noted in prior studies using treatment with
conventional immunosuppressive therapy.
Conclusion: In this retrospective study, we demonstrate the fea-
sibility of using ECP to manage BO occurring after allogeneic
SCT. ECP should be considered as early second-line therapy in pa-
tients developing BO following SCT; however, further study is war-
ranted to confirm these results.367
BONE MARROW AND INTESTINAL BUT NOT PERIPHERAL BLOOD EOSIN-
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Objectives: Acute GvHD remains a severe complication after
RIC-HCT. We report here the predictive value of bone marrow
and intestinal eosinophilia in patients transplanted from 1999 to
2005 by using RIC HCT.
Patients andmethods:One hundred and fifteen patients (55 fe-
male) with haematological malignancies with the median age of 59
years (range 21 to 75) were treated with RIC-HCT for AML (n 5
76), ALL (n 5 7), CML (n 5 13) and MDS (n 5 19). Condition-
ing regimen consisted of fludarabine at day -4 to -2 and 2 Gy total
body irradiation at day 0 followed by the infusion of HCT of an
related (n 5 30), allele matched unrelated (n 5 76) or mismatched
(n 5 9) donor and treatment with MMF and CSA. Bone marrow
and peripheral blood evaluation was performed before and on day
128 after RIC-SCT; Eosinophilia was graduated from 0 to 4. Sys-
tematic colon and/or duodenal biopsies have been performed im-
mediately after first symptoms of gut GvHD. Histological criteria
of gut GvHD were assessed and tissue eosinophils analysed within
the lamina propria and lamina submucosa. The density of
